Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 21 - Drugs for disorders of the muscular or neuromuscular system
Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287)
07/2003
07/03/2003WO2003053219A2 Methods for slowing senescence and treating and preventing diseases associated with senescence
07/03/2003WO2003030823A3 Combinations for the treatment of immunoinflammatory disorders
07/03/2003WO2003013440A3 Treatment and prevention of heat shock protein-associated diseases and conditions
07/03/2003WO2002070657A3 93870, a human g-protein coupled receptor and uses therefor
07/03/2003US20030125615 Homing of autologous cells to a target zone in tissue using active therapeutics or substances
07/03/2003US20030125368 (1,2,4) triazol-1-yl)-benzenesulfonyl derivatives useful to treat osteoarthritis, rheumatoid arthritis, colon cancer and Alzheimer's disease, in mammals; cyclooxygenase (COX)-2 inhibitor
07/03/2003US20030125363 Riluzole and alpha-tocopherol combination
07/03/2003US20030125361 1H-benzo(g)indazole compounds as anticarcinogenic agents and also treat arthritis
07/03/2003US20030125332 Pyrazolo(3,4-c)pyridazin-3-ylamine derivatives; glycogen synthase kinase-3 (gsk-3); treatment and prevention of diabetes and Alzheimer's disease
07/03/2003US20030125330 Anxiolytics and antidepressants
07/03/2003US20030125318 Benzothiazole derivatives with activity as adenosine receptor ligands
07/03/2003US20030125247 A Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants) fused to albumin, is sufficient to prolong the shelf-lilfe of therapeutic protein
07/03/2003US20030124723 Use of a nuclease inhibitor or interleukin-10 (IL-10) for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell and compositions useful in gene therapy
07/03/2003US20030124150 Kit for reducing aching
07/03/2003CA2849201A1 Adipose-derived cell processing unit
07/03/2003CA2470603A1 Methods for the treatment of peripheral neural and vascular ailments
07/03/2003CA2470594A1 Leptin proteins
07/03/2003CA2470576A1 Methods for slowing senescence and treating and preventing diseases associated with senescence
07/03/2003CA2469370A1 Adipose-derived cell processing unit
07/03/2003CA2448811A1 Thiochromenones used to combat painful conditions and neurodegenerative diseases
07/02/2003EP1322769A2 Protein phosphatases
07/02/2003EP1322760A2 G-protein coupled receptors
07/02/2003EP1322613A1 Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases
07/02/2003EP1322590A1 5-amino-1-pentene-3-ol substituted derivatives
07/02/2003EP1322338A2 Compositions and methods of using capsid protein from flaviviruses and pestiviruses
07/02/2003EP1322336A1 Method of increasing testosterone and related steroid concentrations in women
07/02/2003EP1322324A2 Methods for treating muscle injuries
07/02/2003EP1322322A2 Compounds and methods for inhibiting alpha-1 beta-1 integrins
07/02/2003EP1322309A2 High affinity small molecule c5a receptor modulators
07/02/2003EP1224180B1 Substituted azoles
07/02/2003EP1218372B1 Novel heterocyclic compounds useful as reversible inhibitors of cysteine proteases
07/02/2003EP1140861B1 Novel polyhydroxypyrazine derivatives, preparation and pharmaceutical compositions containing same
07/02/2003CN1427840A Azabicyclic carbamates and their use as alpha-7 nicotinic acetyl choline receptor agonists
07/01/2003US6586474 Amidino compounds useful as nitric oxide synthase inhibitors
07/01/2003US6586456 Corticotropin releasing factor (CRF) antagonists such as (4-(2-chloro-4-methoxy-5-methylphenyl)-5-methylthiazol-2-yl)(( (1-(3-fluoro-4-methylphenyl)-2-methoxyethyl))prop-2-ynylamine, prepared by alkylation with propagyl bromide
07/01/2003US6586441 Adenosine receptor ligands and their use in the treatment of disease
07/01/2003US6586422 Pyrazine and triazine derivatives of 1,2,4,5-tetrahydro-Benzo or Thieno [d] azepine
07/01/2003US6585993 Controlled release neurotoxin system
06/2003
06/26/2003WO2003052095A2 Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell
06/26/2003WO2003052048A2 Nucleic acid-associated proteins
06/26/2003WO2003051917A2 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
06/26/2003WO2003051890A1 Imidazo [2,1-b]-1,3,4-thiadiazole suflonamides
06/26/2003WO2003051888A1 6-aminomorphinane derivatives, method for the production and use thereof
06/26/2003WO2003051878A1 Quinolinones as prostaglandin receptor ligands
06/26/2003WO2003051868A1 Lactams as tachykinin antagonists
06/26/2003WO2003051842A2 Compositions decreasing activity of hormone-sensitive lipase
06/26/2003WO2003051841A2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
06/26/2003WO2003051833A2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
06/26/2003WO2003051400A1 Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
06/26/2003WO2003051393A2 Enzymatic cleavable reagents for specific delivery to disease sites
06/26/2003WO2003051369A1 Pharmaceutical containing n, n'-disubstituted piperazine compounds
06/26/2003WO2003051365A2 Use of compounds of the benzamide family as immunosuppressant
06/26/2003WO2003051333A1 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
06/26/2003WO2003051315A2 Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
06/26/2003WO2003051277A2 Novel compounds
06/26/2003WO2003030920A9 An antispasmodic agent spaced drug delivery system
06/26/2003WO2002094202A3 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
06/26/2003WO2002080945A3 Methods for treating the inflammatory component of a brain disorder
06/26/2003US20030120080 Such as (2S)-2-((4S)-4-(2,2-difluorovinyl)-2-oxopyrrolidinyl) butanamide; antiepileptic agents; anticonvulsants
06/26/2003US20030120059 Cell surface molecule-induced macrophage activation
06/26/2003US20030119837 Pharmaceutical composition for the treatment of CNS and other disorders
06/26/2003US20030119835 Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents
06/26/2003US20030119827 Peptidyl carbamates; treatments for osteoporosis and autoimmune diseases
06/26/2003US20030119826 Neuroprotective treatment methods using selective iNOS inhibitors
06/26/2003US20030119820 Substituted indoles
06/26/2003US20030119788 N-cyanomethyl carbonamides and sulfonamides which are cysteine protease, particularly cathepsin K, inhibitors
06/26/2003US20030119786 Combinations for the treatment of immunoinflammatory disorders
06/26/2003US20030119111 G-protein coupled receptor, named 2871 receptor
06/26/2003US20030119095 Novel nucleic acid sequences encoding human vesicle transport protein-like and residue rat-like polypeptides
06/26/2003US20030119076 B7-like polynucleotides, polypeptides, and antibodies
06/26/2003US20030119045 Controlling cell proliferation; adjust adhesion to substrate
06/26/2003US20030118565 Treatment of muscular dystrophy with cord blood cells
06/26/2003US20030118507 Methods of using 46828, a human acyl-CoA synthetase
06/26/2003CA2471777A1 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
06/26/2003CA2471589A1 Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
06/26/2003CA2470236A1 Lactams as tachykinin antagonists
06/26/2003CA2469944A1 Medicaments comprising n, n'-disubstituted piperazine compounds and their use
06/26/2003CA2469799A1 Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell
06/26/2003CA2469048A1 Quinolinones as prostaglandin receptor ligands
06/26/2003CA2468413A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
06/26/2003CA2446292A1 Nucleic acid-associated proteins
06/25/2003EP1320614A2 Novel proteases
06/25/2003EP1320600A1 Transporters and ion channels
06/25/2003EP1320597A2 Induction of exon skipping in eukaryotic cells
06/25/2003EP1320550A2 G-protein coupled receptors
06/25/2003EP1320548A2 Transporters and ion channels
06/25/2003EP1320520A1 Sulfonylguanidine
06/25/2003EP1320363A1 Lactone integrin antagonists
06/25/2003EP1200442B1 2,3-benzodiazepine derivatives
06/25/2003EP1178981B1 Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
06/25/2003EP0752862B1 Use of biopolymers for muscle treatment
06/25/2003CN1426412A Novel compounds
06/25/2003CN1426397A Aminopyridines and their use as anticonvulsants and sodium channel blockers
06/25/2003CN1426394A Novel compounds
06/25/2003CN1426393A Novel compounds
06/25/2003CN1426392A Propenecarboxylic acid amidoxime derivatives, process for preparation thereof, and pharmaceutical compositions containing same
06/24/2003US6583127 Administering phosphatides such as 1-O-octadecyl-2-O-methyl glycero-3-phosphocholine, enantiomers and/or stereisomers as antiinflammatory agents for prophylaxis of inflammatory bowel disease, gastrointestinal or respiratory system disorders
06/24/2003US6582351 Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE
06/24/2003CA2165566C Conotoxins having acetylcholin receptor binding properties
06/19/2003WO2003050128A1 Phosphonates useful as modulators of t $g(g)9$g(d)2 lymphocyte activity
1 ... 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 ... 233